John Bossaer

💡 🧠 Hot off the press in its entirety... Our multi-center study looking into the safety of MMR vaccination in patients with myeloma receiving daratumumab maintenance after ASCT! Out now in @BloodPortfolio #BloodNeoplasia doi.org/10.1016/j.bneo…

@FDAOncology The Xeldo PI link currently active on this site goes to a 12/2022 update…makes it pretty tough to see the changes to label if the most current label isn’t correct on the hyperlink…

#FDA announces safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. fda.gov/drugs/resource…

Characterizing Patient-Reported Outcome Data Availability for Oral Anticancer Therapies. Co-authored by @PharmDeetinib. Read the full article. brnw.ch/21wYgR9

Belantamab mafodotin

On a 1-10 scale of things I wouldn't have believed before reading them, this is an 11 👀 🇩🇪 analysis in @ASTCT_Journal of spleen size (assessed by CT) and outcomes in BCMA CAR-T in #MMsm. Splenomegaly has worsened outcomes, possibly driven by CAR T-cell sequestration (!)

@RBeechPharmD I know X isn’t what Twitter used to be, but there is still some joy to be found on here

I fucking knew it

Mark Your Calendars - April 3 is now officially Oncology Pharmacist Day! This is the same date when HOPA was founded back in 2004. We can't wait to celebrate the first ever #OncologyPharmacistDay in 2026! Find out more details here: bit.ly/48JHKoy

Interesting. Wasn’t aware of possible interference with biotin and certain labs and immunoassays common to cancer patients

FDA's oncology OS draft guidance emphasizes pre-specified survival analysis plans. No more post-hoc scrambling—sponsors need upfront protocols for timing, methods, censoring strategies & sensitivity analyses. fda.gov/regulatory-inf…

Well, I looked at the CTCAE v6 vs v5 with tracked changes. dctd.cancer.gov/research/ctep-… Here are some heme/onc focused updates:

Talquetamab-induced dizziness- ataxia syndrome, clinical presentation and management by @JanakiramMurali 🧵 1/🚨 New neurotoxicity alert in multiple myeloma care! A distinct “dizziness-ataxia syndrome” has been linked to talquetamab 🧪—the first FDA-approved drug targeting GPRC5D for heavily pretreated RRMM. Here’s what clinicians need to know. ⬇️ #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما

Role of a Designated Pharmacist in Reducing Adverse Drug Reaction Rates and Preventing Potential Medication Errors in Hematology-Oncology: A Randomized Controlled Trial. Read the full article. brnw.ch/21wUJRF

Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology brnw.ch/21wUzDq

Fantastic episode and fantastic study focusing on the principle that doses matter!

Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma | Journal of Clinical Oncology ascopubs.org/doi/abs/10.120…

👥 Join experts Alexis Kuhn, Bhavesh Shah, and Vivian Tar, at the #ATOPPSummit on July 9-11, for a deep dive into gene therapies for sickle cell disease. This program will equip clinicians, administrators, and access specialists with the knowledge needed. 📚 Don't miss out! 🕐

We are excited to announce that CE credit obtained at the ATOPP Summit can now be used towards BCOP recertification! 🎉 ✨ The 2025 ATOPP Summit provides 8.25 CPE hours. For more info about the new BPS pilot program, see here: #FAQS" target="_blank" rel="nofollow noopener">atoppsummit.com/contact#FAQS!

FDA announces 30-day public comment period on DPD deficiency testing before fluorouracil/capecitabine chemotherapy. Medical professionals: We need your expertise on testing challenges, decision factors, and treatment approaches for affected patients. federalregister.gov/documents/2025…

Spring is in the air, and so is innovation in oncology pharmacy! 🌿 What’s one new idea you're bringing to your practice this year? Drop your thoughts! 👇 #ATOPP2025 #LeadingTowardTomorrow